Objective-Vasculogenic progenitor cell therapy for ischemic diseases bears great potential but still requires further optimization for justifying its clinical application. Here, we investigated the effects of in vivo tissue engineering by combining vasculogenic progenitors with injectable scaffolds releasing controlled amounts of proangiogenic growth factors. Methods and Results-We produced biodegradable, injectable polylactic coglycolic acid-based scaffolds releasing single factors or combinations of vascular endothelial growth factor, hepatocyte growth factor, and angiopoietin-1. Dual and triple combinations of scaffold-released growth factors were superior to single release. In murine hindlimb ischemia models, scaffolds releasing dual (vascular endothelial growth factor and hepatocyte growth factor) or triple combinations improved effects of cord blood-derived vasculogenic progenitors. Increased migration, homing, and incorporation of vasculogenic progenitors into the vasculature augmented capillary density, translating into improved blood perfusion. Most importantly, scaffold-released triple combinations including the vessel stabilizer angiopoietin-1 enhanced the number of perivascular smooth muscle actin ϩ vascular smooth muscle cells, indicating more efficient vessel stabilization. Conclusion-Vasculogenic progenitor cell therapy is significantly enhanced by in vivo tissue engineering providing a proangiogenic and provasculogenic growth factor-enriched microenvironment. Therefore, combined use of scaffoldreleased growth factors and cell therapy improves neovascularization in ischemic diseases and may translate into more pronounced clinical effects. (Arterioscler Thromb Vasc Biol. 2010;30:1897-1904.)
I schemic diseases such as peripheral artery disease and coronary artery disease are devastating diseases of the cardiovascular system caused by lack of sufficient blood supply for skeletal or cardiac muscles. To date, these diseases are on the rise because of an increasing elderly population and the prevalence of obesity and diabetes mellitus. Moreover, conventional therapies, including surgical treatments, are not yet sufficient to promote adequate recovery of the blood flow in ischemic areas. 1 Initially, growth factor-based approaches without additional cell application were widely used to enhance neovascularization, but the rapid protein degradation in vivo hinders a sustainable success. 2 More recently, cell-based therapies have attracted great interest, as improved neovascularization in both experimental hindlimb ischemia models and clinical studies could be demonstrated. 3, 4 Because the outcome of patients is still poor, optimization protocols for enhanced cell therapy have emerged. 5, 6 In this context, injection of biodegradable scaffolds in vivo with controlled release of proangiogenic growth factors 7 facilitated in vivo tissue engineering and compensated for the disadvantage of in vitro-engineered 3-dimensional tissues lacking appropriate vascularization.
Here, we investigated the combined effects of vasculogenic cell therapy with scaffolds delivering proangiogenic growth factors in a protracted manner. Biocompatible polylactic coglycolic acid (PLGA) microparticles were used as injectable scaffolds. 8 Their gradual degradation into water-soluble, nontoxic products can be controlled by choosing polymers with release profiles ranging from 1 week to several months. Because dual and multiple growth factor-based therapeutic approaches have been reported to be superior to singlegrowth factor therapy, 9 -11 we used a mixture of dual and triple combinations of proangiogenic growth factors. The combination of hepatocyte growth factor (HGF) and vascular endothelial growth factor (VEGF) has resulted in a more robust proangiogenic response. 12 We therefore also designed scaffolds incorporating VEGF and HGF as basic proangiogenic growth factors along with additional vessel-stabilizing angiopoietin-1 (Ang-1) with and without concomitant infusion of cord blood-derived vascular progenitors. 13
Methods
For more information, see supplemental material, available online at http://atvb.ahajournals.org.
Animals
Animal procedures performed for this study were all approved by the Institutional Animal Care and Use Committee of the Spanish National Cancer Research Centre and the Administrative Panel on Laboratory Animal Care (Government of Upper Bavaria, Germany).
Scaffold Preparation
Microparticles containing individual growth factors were produced using a double-emulsion technique as previously described. 8
Isolation of Human Cord Blood-Derived Vasculogenic Progenitor Cells
Isolation of ECFC was performed by density gradient centrifugation with Ficoll as previously described. 13
Chicken Chorioallantoic Membrane Assay
Chorioallantoic membrane assays were performed on 4-day-old eggs. After a window was cut, the scaffolds with or without growth factors were placed into the egg, which was sealed and incubated for 6 days at 37°C.
Matrigel Plug In Vivo Assay
VEGF, HGF, and Ang-1 incorporated into PLGA scaffolds were mixed with growth factor-reduced Matrigel (BD Biosciences) and subcutaneously implanted into nude mice. After 1 week, fluorochrome-conjugated lectin was administered intravenously as described previously. 14
Hindlimb Ischemia Model
Unilateral hindlimb ischemia was induced as described previously. 15, 16 
Histological Analysis of Ischemic Muscles
Capillaries were scored in frozen sections of the adductor muscles by staining for CD31-allophycocyanin (APC) (BD Biosciences). Conductant vessels were stained by smooth muscle actin (SMA)-Cy3 or SMA-fluorescein isothiocyanate (Sigma-Aldrich). Human ECFC were detected by human-specific APC-conjugated human leukocyte antigen (HLA)-ABC (Biolegend).
Results

Scaffold-Derived Proangiogenic Growth Factors Enhance Neovascularization in Matrigel Plugs
First, we produced 50 to 100 m microparticles containing VEGF, HGF, and Ang-1, which were designed to release their incorporated proangiogenic growth factors for up to 2 weeks. Scanning electron microscopy indicated that the microparticles had a spherical shape with smooth surface ( Figure 1A ). We then tested the effectiveness of single, double, and triple sets of scaffold-released growth factors in vivo in Matrigel plugs. Local delivery of the single growth factors in Matrigel plugs resulted in an increased vessel growth, as shown by intravenous lectin injection visualizing the vascular network ( Figure 1B and 1C; Supplemental Figure VA ). All growth factor-containing scaffolds induced a significantly (PϽ0.05) increased vessel growth compared with growth factor-free scaffolds (blank). The efficacy of the dual combination of scaffold-released VEGF and HGF on the vascular network formation was superior to VEGF alone, and the triple combination of VEGF, HGF, and Ang-1 was superior to the double combination of VEGF and HGF ( Figure 1B and 1C ). Therefore, we decided to proceed using the dual and triple combination of scaffold-released growth factors for our further experiments in an ischemic setting.
Scaffolds Releasing the Dual Combination of VEGF and HGF in Combination With Vasculogenic Progenitors Enhance Neovascularization in Hindlimb Ischemia Models
We intramuscularly injected scaffolds releasing VEGF and HGF in a model of unilateral hindlimb ischemia. Here, we combined growth factor therapy with a cell therapeutic approach using cord blood-derived ECFC (Supplemental Figure I ). Using this combinational approach, we could demonstrate as a proof-of-concept that the scaffold-mediated release of VEGF and HGF increased the blood flow in the ischemic hindlimb ( Figure 2A ). The additional presence of vasculogenic progenitor cells administered either intravenously or intramuscularly further enhanced perfusion. In particular, intramuscularly injected vasculogenic progenitor cells, which on their own exhibited only a small increase in perfusion, 6 profited most from the additional scaffolddelivered growth factors. These data could be confirmed by measuring the microvessel density in the ischemic adductor muscles ( Figure 2B and 2C). To evaluate the migration and subsequent homing of intravenously administered ECFC to the ischemic site, we identified human ECFC by staining with human-specific HLA-ABC antibodies ( Figure 2D ; Supplemental Figure IVB and IVC). We found significantly (PϽ0.05) increased numbers of human HLA ϩ cells in the ischemic muscles of mice that had received VEGF and HGF-secreting scaffolds compared with blank scaffolds (Figure 2D and 2E). Likewise, the number of human ECFC that had incorporated into the vasculature was also more pronounced ( Figure 2D and 2F). These data imply that in vivo tissue engineering using a combination of injectable VEGF and HGF-releasing scaffolds and additional vasculogenic cell therapy improves local vessel growth, homing, and incorporation of vasculogenic progenitor cells, resulting in restored blood flow.
Scaffold-Derived Ang-1 Further Improves Neovascularization Induced by VEGF and HGF
The effects of different factors and their combinations were further investigated in a chick chorioallantoic membrane assay. Blank or growth factor-containing scaffolds were covered with filter paper and placed into a fertilized egg. After 6 days, scaffolds containing Ang-1 alone significantly (PϽ0.05) increased neovascularization compared with blank scaffolds ( Figure 3A and 3B). Most importantly, Ang-1 further significantly (PϽ0.05) enhanced neovascularization when combined with VEGF and HGF.
Scaffolds Releasing Ang-1 Reduce VEGF-Mediated Vascular Leakage
In addition to its proangiogenic action, Ang-1 is also known to stabilize newly formed vessels. 17 Using an ear tissue leakage assay, 18 we show that VEGF alone drastically decreases vascular integrity, as evidenced by enhanced extravasation of intravenously injected Evans blue, whereas Ang-1 alone showed a pronounced reduction of Evans blue leakage ( Figure 4A and 4B; Supplemental Figure VB) . Interestingly, the combination of HGF and VEGF already reduced the leakage caused by VEGF alone. These positive effects were further enhanced by the coadministration of Ang-1. The triple combination of VEGF, HGF, and Ang-1 induced formation of significantly more vessels compared with the dual combination ( Figures 1B, 1C , 3A, and 3B), which are significantly (PϽ0.05) less leaky than those induced by the dual combination of VEGF and HGF.
Scaffolds Releasing the Triple Combination of VEGF, HGF, and Ang-1 in Combination With Vasculogenic Progenitors Efficiently Enhance Neovascularization in Hindlimb Ischemia Models
Finally, we set out to test whether the triple combination of growth factors including the vessel stabilizing factor Ang-1 might further improve the effects of vasculogenic progenitor cells. Here, we focused on intravenous ECFC injection, because we obtained more pronounced treatment results using this route of administration. We observed a robust increase in perfusion using the triple growth factor combination and intravenous ECFC injection, as shown by laser Doppler measurements ( Figure 5A ). In addition, we performed near-infrared in vivo imaging of indocyanine green distribution using an IVIS-200 noninvasive optical imaging device; this imaging further underlined the effect of the triple growth factor combination along with ECFC compared with blank controls ( Figure 5B ). The triple scaffold combination plus ECFC reduced the presence of toe necrosis and efficiently restored the blood flow ( Figure 5B ). Histologically, these effects correlated strongly with increased numbers of SMA conductant vessels in the adductor muscles ( Figure 5C and 5D). Of note, only the triple combination of scaffoldreleased growth factors, not the dual combination, increased numbers of SMA ϩ conductant vessels ( Figure 5C ). Interestingly, pericytes were not derived from infused ECFC (Sup-plemental Figure II) . These data suggest that a combination of the 3 growth factors VEGF, HGF, and Ang-1 robustly improved neovascularization by strongly increasing the number of vascular smooth muscle cells, including pericytes. 
Discussion
In the present study, we show that the effects of vasculogenic cell therapy can be additively enhanced by the release of proangiogenic growth factors delivered by injectable microparticle-based scaffolds in a murine model of hindlimb ischemia. Vasculogenic cell therapy using cord blood-derived ECFC was most efficiently enhanced in the presence of scaffolds releasing a triple growth factor combination of VEGF, HGF, and Ang-1. Using this combination, we observed a robust increase in perfusion of the ischemic hindlimb. We assessed the functional improvements by noninvasive in vivo analyses using laser Doppler-derived blood flow measurements and optical imaging. These in vivo measurements were corroborated by corresponding increases in homing and incorporation of intravenously administered cells, microvessel density, and the number of SMA ϩ vascular smooth muscle cells representing perivascular mural cells essential for vessel stabilization. Moreover, the triple combination containing Ang-1 reduced vascular permeability.
Clinical needs for vascular regeneration in the treatment of ischemic peripheral artery disease and myocardial infarction are still unmet. Although the results of experimental and first clinical studies investigating cardiovascular cell therapy were promising, the overall level of the therapeutic effects clearly indicates that additional strategies will be necessary to enhance the proangiogenic effects of cell therapy. 19 This could be achieved in a variety of ways, but combinational approaches seem to be most promising. To date, some investigators have focused on combining different cell sources to produce more pronounced effects with respect to tissue neovascularization. 20, 21 In these experimental settings, vasculogenic progenitor cells were coadministered along with cell types replacing the function of pericytes, which are essential for producing mature and stable vascular networks. However, the implementation of different cell types sometimes requires invasive procedures and renders the therapeutic approach even more personalized, limiting its broader clinical application. Another strategy is to combine cell therapeutics with additional growth factors. Interestingly, a very recently published study using VEGF and HGF gene therapy combined with mesenchymal stem cells showed beneficial effects on cardiomyocyte survival and function in myocardial infarction models. 22 However, gene therapy approaches can bear safety risks that may limit their clinical application.
Here, we use a novel dual approach strategy involving ECFC and multiple scaffold-released growth factors for vascular tissue regeneration. Growth factor-releasing scaffolds providing the matrix for coadministered ECFC represent a new in vivo tissue engineering approach. Injectable scaffolds are an emerging concept for tissue engineering purposes and have initially been used for bone and cartilage regeneration. 23 Incorporated growth factors stimulate local vascularization of the host tissue and support and attract simultaneously injected stem and progenitor cells. In the past, less well-characterized matrices, such as collagen, have been used to support local cell injection and restoration of vascular networks. 24 However, these matrices do not provide controlled release of defined growth factors, making them less suitable for clinical applications.
In this report, we used PLGA microparticles as scaffolds, because they represent a defined drug delivery system that is injectable, biodegradable, and approved by the US Food and Drug Administration, making them attractive candidates for clinical vascular tissue engineering. Microparticles have the advantage that they can be specifically designed for longterm release over months. The sustained release of erythropoietin using biodegradable gelatin hydrogel microspheres has very recently been reported to persistently improve hindlimb ischemia. 25 However, hydrogels do not offer protection during release in in vivo environments. Moreover, PLGA microparticles allow a variety of factors to be incorporated, including hydrophobic substances that might not be suitable for hydrogels.
In our experimental setup, the scaffold mixture was injected into the ischemic muscle, followed by vasculogenic progenitor cell therapy. In contrast to Bible et al, 8, 26 we did not attach our vasculogenic progenitors to the surface of the microparticles, because we administered our cell therapy by intravenous and intramuscular routes for direct comparison of the optimal route of delivery. Because of the relatively large size of the microparticles ranging from 50 to 100 m, intravascular delivery may potentially lead to microembolism and should be avoided. Moreover, as a further improvement compared with Bible et al, 8, 26 we used scaffolds releasing up to 3 growth factors.
Optimal results were obtained using injectable scaffolds releasing a multifactorial growth factor combination that included the 2 proangiogenic growth factors and chemoattractants VEGF and HGF, as well as Ang-1 with additional vessel stabilizing capacities. Although VEGF is the classic factor to induce vascularization, it has been shown to have dichotomous roles and is a known mediator of inflammatory responses and microvascular permeability leading to edema. 12, 27 Recently, inhibition of vascular smooth muscle cells, including pericytes, has been reported as another unexpected effect of VEGF. 28 Interestingly, these data imply that VEGF might even retard, not promote, tumor progression. 29 Therefore, we decided to use additional proangiogenic growth factors, namely Ang-1 and HGF. Vascularization is regulated mainly by the interplay between VEGF and the angiopoietin system, in which Ang-1 acts as an essential factor for vessel maturation. 17 Ang-1 has also been reported to have a chemotactic effect on bone marrow-derived hematopoietic stem cells expressing the Ang-1 receptor Tie2, thereby inducing recruitment of hematopoietic stem cells. 30 Mobilized hematopoietic stem cells may then undergo Ang-1-induced endothelial differentiation as previously reported, 31, 32 further facilitating neovascularization. However, enhanced endothelial commitment seems to be restricted to undifferentiated hematopoietic stem cells, because endothelially committed ECFC did not respond to Ang-1 pretreatment (Supplemental Figure III) .
In addition, we used HGF, a potent endothelial mitogen that has been shown to enhance vascularization without inducing vascular permeability. 33 Moreover, HGF has been shown to mediate the Ang-1-induced pericyte recruitment and seems to lack proinflammatory effects. 34, 35 Therefore, in our experiments, the triple combination of scaffold-released VEGF, HGF, and Ang-1 resulted in a robust enhancement of vascularization that was superior to any of the administered factors alone. The increased muscular capillary density and the enhanced number of arterioles/arteries (conductant vessels) clearly demonstrate the increased capacity of our coadministered scaffold-released growth factors and vasculogenic progenitor therapy to promote therapeutic neovascularization. The increased number of SMA ϩ smooth muscle vascular cells and pericytes in the presence of the triple scaffoldreleased growth factor combination indicated sufficient vessel stabilization and maturation.
For our studies, we used cord blood-derived ECFC, which bear greater potential for cell-based clinical therapies compared with dysfunctional autologous patient-derived progenitors, 36 provided they are transplanted in an HLA-matched manner. 37 Finally, the beneficial effect of our combinational approach of scaffold-based growth factor release including in vivo cell therapy is strongly supported by a recent report. 38 In this study, release of VEGF from an alginate matrix strongly supported coadministered vasculogenic progenitor cells, whereas intramuscular injection of the cells together with a bolus injection of VEGF was only minimally effective. 38 In conclusion, our results demonstrate that vasculogenic progenitor cell therapy can be very efficiently enhanced by a suitable controlled-release microenvironment of growth factors and chemoattractants. Therefore, we propose this scaffold-based multifactorial growth factor approach as a novel optimization strategy to promote neovascularization in ischemic peripheral artery disease. 
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